To clarify the underlying mechanism SLC2A3 in the progression of CRC, GSEA enrichment showed SLC2A3 was involved in EMT pathway and immune response, and SLC2A3 expression was positively correlated with mesenchymal markers and immune reactive-related checkpoints such as PD-L1, PD-L2, LAG3, CTLA4, and TIM3. The gene discussed is SLC2A3; the disease is colorectal carcinoma.